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ABSTRACT: Liposome-based drug delivery systems composed of DOPE stabilized with
cholesteryl hemisuccinate (CHMS) have been proposed as a drug delivery mechanism with
pH-triggered release as the anionic form (CHSa) is protonated (CHS) at reduced pH;
PEGylation is known to decrease this pH sensitivity. In this manuscript, we set out to use
molecular dynamics (MD) simulations with a model with all-atom resolution to provide insight
into why incorporation of poly(ethyleneglycol) (PEG) into DOPE−CHMS liposomes reduces
their pH sensitivity; we also address two additional questions: (1) How CHSa stabilizes DOPE
bilayers into a lamellar conformation at a physiological pH of 7.4? and (2) how the change from
CHSa to CHS at acidic pH triggers the destabilization of DOPE bilayers? We found that (A)
CHSa stabilizes the DOPE lipid membrane by increasing the hydrophilicity of the bilayer
surface, (B) when CHSa changes to CHS by pH reduction, DOPE bilayers are destabilized due
to a reduction in bilayer hydrophilicity and a reduction in the area per lipid, and (C) PEG
stabilizes DOPE bilayers into the lamellar phase, thus reducing the pH sensitivity of the liposomes by increasing the area per lipid
through penetration into the bilayer, which is our main focus.
KEYWORDS: molecular dynamics simulations, PEGylated pH-sensitive liposomes, cholesteryl hemisuccinate, phase transition,
bilayer hydrophilicity
1. INTRODUCTION
Lipid bilayers are of great importance in pharmaceutical
nanotechnology. They can be formed into liposomes that can,
in turn, be used as a nanoscale delivery system for small drug
molecules,1−4 nucleic acids,4−7 and proteins.8 The dominant
mechanism through which liposomes enter the cell is
endocytosis, where they undergo enzymatic degradation by
lysosomes.9 To disrupt this process, pH-sensitive liposomes
have been proposed; in an acidic environment found within
endosomes, they can destabilize the endosomal membrane,
disrupting the formation of the lysosomal environment.9 pH-
sensitive liposomes are formulated from a variety of lipid
molecule types with the pH sensitivity achieved through
several different possible mechanisms. For example, liposomes
that have been designed to undergo a change in conformation
in response to protonation/deprotonation10−13 become
unstable through cleavage of the protective poly-
(ethyleneglycol) (PEG) corona due to chemical reactions
induced by pH change,14,15 or, as proposed by Nahire et al.,
generate gas bubbles in response to low pH as a result of
encapsulation by a precursor; the escaping gas bubbles disturb
membranes and facilitate liposome content release.16 Change
in the protonation state can increase drug solubility, thus
triggering either release17 or transformation into a surfactant
destabilizing liposome.18 Also, Mamasheva et al. constructed
liposomes in which pH change triggers phase separation.
Liposomes that have undergone phase separation remain stable
but have increased permeability, and thus they slowly release
their drug payload; the achieved controlled release can be
advantageous in cancer therapy.19 Finally, Phoeung et al.
demonstrated that large unilamellar vesicles composed of
palmitic acid and cholesterol or cholesteryl sulfate released
their content in response to pH changes.20 This case is
particularly interesting as, in liposomes containing cholesterol,
the protonation of palmitic acid occurs with a decrease in pH,
triggering the release at low pH, whereas in the case of
liposomes containing cholesteryl sulfate, the deprotonation
occurs with increasing pH, triggering the release to occur at
high pH.
Among all classes of pH-sensitive liposomes, the leading
choice for the main phospholipid is phosphatidylethanolamine
(PE).21,22 Preparation of stable bilayer vesicles from di-oleoyl
PE (DOPE), at a physiological pH of above 10 °C, is however
not possible23 unless either another lipid, e.g., phosphatidyl-
choline (PC), at greater than 30 mol % or an amphiphilic
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stabilizer with a carboxyl group is added.24 Cholesteryl
hemisuccinate is the most popular choice in this regard,25,26
used extensively in the preparation of pH-sensitive liposomes
in combination with DOPE. Although stable DOPE liposomes
can only be made at high pH (>9.0) where PE is negatively
charged,27 incorporation of cholesteryl hemisuccinate
(CHMS) into DOPE liposomes stabilizes them into the
lamellar phase at a physiological pH of 7.4;28 at 25 °C, the
addition of CHMS in excess of 20 mol % stabilizes DOPE
vesicles.29 The structure of the CHMS molecule includes a
carboxylic acid group with a pKa of 5.8; its ionic state
determines the phase behavior of the DOPE ensemble.28 At
physiological pH, the vast majority (98%) of CHMS is in the
deprotonated (anionic) form30 and thus is negatively charged
(in this article, we refer to the anionic form of CHMS as
CHSa); in an acidic environment, CHMS is protonated and
thus becomes neutral (in this article, we refer to the neutral
form of CHMS as CHS).
Although there is general agreement that CHSa stabilizes
DOPE bilayers through a change in phase behavior of the lipid
ensemble, several different mechanisms have been proposed
for how the bilayer is stabilized. Lai et al. proposed that the
membrane-stabilizing effect of CHSa is probably due to the
disruption of the intermolecular interaction between adjacent
PEs,29 whereas Torchilin et al. attributed the CHSa stabilizing
effect to its ability to increase liposomal interfacial hydration.31
Yet other studies consider the electrostatic repulsion provided
by CHSa as the stabilizing mechanism.28
The protonation of CHMS (transformation from CHSa to
CHS) leads to the rapid destabilization of liposomes; CHS
lacks the membrane-stabilizing properties of CHSa. It is
noteworthy that cholesterol (CHOL) also decreases the
stability of the 1-palmitoyl-2-oleoyl-phosphatidylethanolamine
(POPE)/CHOL lamellar phase when its concentration in the
lipid mixture is increased from 0 to 30%. Interestingly, a
further increase of the CHOL concentration reversed this
effect.32 However, the atomistic details leading to the
destabilization of CHMS/DOPE lamellar phases are not
clearly understood. This is due to the inherent complexity of
the process, which involves the formation of intermediate
structures; it is known that with a reduction in pH, DOPE−
CHSa transforms into DOPE−CHS, leading to liposomal
aggregation and inter bilayer contact and ultimately disruption
of the liposomes.27 The contact-induced destabilization does
not, however, lead to any mixing of aqueous contents of
liposomes;33 it only causes lipid mixing at pH of 5 or below.34
Liposomes are successful drug delivery systems in vitro;
however, their application is hindered by rapid clearance from
the blood stream following injection. To increase the
circulation half-life of liposomes, they are sterically stabilized
by PEGylation through incorporating PEGylated lipids into the
liposome formulation.1,2,21 Although PEGylation significantly
increases the circulation half-life of liposomes, it also
unfortunately causes a dramatic reduction in pH sensitivity.
DOPE−CHMS liposomes release 55% of their loaded calcein
at a pH of 5.5, whereas PEGylated DOPE−CHMS liposomes
with 0.6 mol % DSPE-PEG2000 release only 24% and only
10% in the case of 3 mol % DSPE-PEG2000.35 Slepushkin et
al. also reported that when 5 mol % DSPE-PEG is incorporated
into DOPE−CHMS liposomes, the release of calcein in buffer,
with pH 5.5, decreases from 84 to 6.8%.36
It has been experimentally proven that a lamellar-to-
hexagonal phase transition occurs following the change of
CHSa into CHS.27,33,34 Although it is not practically feasible to
investigate the whole process of this phase transition using all-
atom MD simulations, large-scale simulations of lipid systems
already in the hexagonal phase have been carried out for
DOPE, POPE,37 and galactolipids,38 and using coarse-grained
simulations, the phase transition of DOPE lipids from lamellar
to hexagonal has been modeled;39 it is however not possible to
investigate the effect of PEGylation on this transition as
current coarse-grained models of PEG fail to reproduce the
relevant properties of PEG. In this study, using all-atom MD
simulations, our focus is to elucidate the effect of charged and
neutral forms of CHMS on the properties of DOPE lipid
bilayers with and without PEGylation. This information helps
to understand the atomistic details governing the change of
stability and consequently the pH sensitivity of DOPE/CHMS
liposomes upon CHMS protonation and the effect of
PEGylation on this, which is the primary focus of this work.
Despite the crucial role of CHMS in the formation and
function of pH-sensitive liposomes, as of yet, no computational
simulations have been conducted on DOPE bilayer containing
CHMS. The only published MD simulations of CHMS in lipid
membranes are the two works performed by Kulig et al.
concerning the similarity of the behavior of CHMS and
cholesterol in saturated and unsaturated PC bilayers.30,40
During the last 10 years, our group has conducted MD
simulations on lipid bilayers and PEGylated liposomes,41−47
where the effect of the presence of PEG, its grafting density,
molecular weight, and conformation on structural character-
istics and behavior of the membrane have been evaluated in
detail. We now continue this line of research; in this
publication, we shed light on the reason why PEGylation
reduces the pH sensitivity of DOPE−CHMS liposomes. We
have additionally addressed two other questions: (1) how
CHSa stabilizes DOPE bilayers in lamellar conformation at a
physiological pH of 7.4 and (2) how the change from CHSa to
CHS at acidic pH triggers the destabilization of DOPE
bilayers; to this end, we have conducted MD simulations using
six model systems as summarized in Table 1.
2. METHODS
2.1. System Setup. We have conducted MD simulations
on six systems. Three of them are non-PEGylated, where the
bilayer is composed of 192 DOPE phospholipids (we refer to
Table 1. Detailed Description of the Composition of All of the Six Simulated Systems
system abbreviation DOPE CHOL CHS CHSa PEG Na+ Cl− K+ water MD length (ns)
DOPE−CHOL 192 96 0 0 0 30 30 0 12 140 300
DOPE−CHS 192 0 96 0 0 30 30 0 12 140 300
DOPE−CHSa 192 0 0 96 0 30 30 96 12 044 300
PEG−DOPE−CHOL 192 96 0 0 14 70 70 14 30 144 400
PEG−DOPE−CHS 192 0 96 0 14 70 70 14 30 144 400
PEG−DOPE−CHSa 192 0 0 96 14 70 70 110 30 048 400
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phospholipids as lipids in this article) and 96 steroid
molecules: cholesterol (CHOL), CHS, or CHSa. In the
other three simulated systems, the bilayer is composed of 192
lipids, 14 of which are PEGylated (PEGylated DOPE lipids)
and 96 of which are steroid molecules. The detailed
description of the components for all six systems is shown in
Table 1, and their chemical structures are displayed in Figure
1. The membranes were constructed using an in-house python
script. This script creates a randomized organization of
provided lipids and steroid molecules based on their
proportions in a bilayer format. Following solvation, in all
systems, 125 mM NaCl was added and K+ counter ions were
used where necessary to obtain charge neutrality for all
systems. Before starting the MD simulations utilizing a
Gromacs 4.6.7 software package,48,49 the starting configura-
tions of the lipid bilayers were energy minimized using the
steepest descent method to remove any possible bad contacts
among the atoms and then simulated for 100 ns with position
restraints on the lipid head group and tail C atoms with a force
constant of 1000 kJ/(mol nm2) in the Z direction. This was
followed by a 200 ns simulation without restraints to relax the
membrane for obtaining the starting configuration of the
membranes. Since the liposomes have a diameter of ∼100 nm
and the box dimension of our simulated slab of the bilayer is
∼8 nm, curvature effects can be assumed to be negligible.
2.2. Molecular Model Parametrization. We used the all-
atom optimized parameters for the liquid simulations (OPLS-
AA) force field50,51 for the parametrization of the steroids,
PEG, and ions. For the lipids, in addition to the OPLS-AA
force field, we used additional parameters from the force field
we recently developed, specially for lipids compatible with the
OPLS-AA force field.52−54 For water, we employed the
compatible TIP3P model.55
2.3. Molecular Dynamics Simulation Parameters. For
all MD simulations, the pressure was controlled at a constant
pressure of 1 bar using the Parrinello−Rahman barostat56 with
a pressure coupling constant of 1 ps and a compressibility of
4.5 × 10−5 bar using a semi-isotropic pressure scheme. The
temperatures of the solute and solvent were set to 310 K,
controlled independently using the Nose−Hoover thermo-
stat.57,58 Periodic boundary conditions, with the usual
minimum image convention, were used in all three directions
(x, y, and z). The Linear Constraint Solver (LINCS)
algorithm59 was used to preserve covalent bond lengths, and
the simulation time step was set to 2 fs. The Lennard−Jones
interactions were calculated within a 1.0 nm cutoff; for the
Figure 1. Chemical structure of the components of the bilayer showing atom numbering for the acyl chains of DOPE and the partial charges
derived for CHOL, CHS, and CHSa.
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electrostatic interactions, we employed the particle mesh
Ewald method.60,61
2.4. Analysis. We performed all of the analysis on the last
100 ns of the trajectory; monitoring of the area per molecule
assured us that all systems had reached equilibrium. We
calculated the averaged area per molecule by dividing the total
area of the simulation box in the x−y plane by the number of
all molecules (lipids and steroids) in a single leaflet and then
averaging it over all of the frames of the last 100 ns of the
trajectory.
Following the calculation of the area per molecule, we
continued our analysis with visualizations of the systems using
visual molecular dynamics (VMD)62 to obtain an intuitive
picture of the behavior and interactions of the components of
the simulated systems. The solvent-accessible surface area
(SASA) value for the hemisuccinate moieties of CHS and
CHSa was measured over the course of the simulation time
with a solvent probe radius of 1.4 Å, using analysis tools found
within the VMD software package. To investigate the
interactions of the ions with both the lipid bilayers and PEG,
the percentage of Na+ ions in contact was calculated; a contact
was considered to exist when the distance between any pair of
atoms from the respective groups was equal to, or less than,
0.325 nm.63
To estimate the extent of lipid chain ordering, we then
measured the average values of the deuterium order parameters
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(1)
where θ is the angle between the C−D bond and the bilayer
normal, and ⟨...⟩ denotes averaging over time and all lipid
molecules;64 SCD was calculated using the gmx_order tool
included in the Gromacs simulation package.
Finally, the mass density profile perpendicular to the
membrane normal for PEG oxygen atoms, lipids, and water
molecules was calculated for each system utilizing the
gmx_density tool of the Gromacs package. Mass density
profiles of different systems were shifted such that the
distributions of the phosphate groups overlap; this allows for
a direct comparison of the depth of penetration of water and
PEG into the bilayer.
3. RESULTS
3.1. Area Per Molecule. The effect on the area per
molecule resulting from alteration of the steroids in the
formulation and the addition of PEG was determined.
Averaged values of the area per molecule for all systems are
shown in Figure 2. Replacement of CHOL with CHSa does
not affect the area per molecule in the absence of PEG and
slightly decreases the area in the presence of PEG. When
CHSa changes to CHS, the area per molecule decreases.
3.2. Membrane Hydration. In Figure 3A, we show the
mass density profiles for water relative to the position of the
phosphate head group. Two clear trends are observed: water
penetration is the deepest for the bilayers with CHOL, and
PEGylation is seen to reduce the degree of water penetration.
In agreement with our observations regarding the depths of
water penetration into the bilayer and area per molecule, the
number of bilayer−water contacts is similar in the bilayers with
CHOL and CHSa and reduced in the bilayers with CHS
(Figure 3B). Next, PEGylation decreases the number of
water−bilayer contacts and H-bonds in all studied models
(Figure 3 B). In agreement with all of the above results, the
SASA was found to be larger for CHSa than that for CHS
(Figure 3C). The observed differences between bilayers
containing CHSa and CHS result from the charged nature of
CHSa, the more polar form of the molecule. The decreased
hydration of the lipids in bilayers containing PEGylated lipids
(Figure 3A,B) results simply from direct coverage of lipids by
PEG (Figure 3C). This result is in agreement with prior
studies by Tirosh et al., who reported that grafting PEG to
liposomes at 5−7 mol %, will decrease hydration of the lipid
head group.65
3.3. Number of Intra-Bilayer H-Bonds. Table 2 shows
the numbers of lipid−lipid, lipid−steroids, and lipid−PEG H-
bonds. The number of H-bonds for the DOPE−CHOL
bilayer, both DOPE−DOPE and DOPE−CHOL, is lower than
that of the DOPE−CHS/CHSa bilayers. The number of
sterol−lipid H-bonds in DOPE−CHSa is more than doubled
in comparison to that in DOPE−CHOL; this probably acts to
compensate for the electrostatic repulsion force between the
CHSa head groups, preventing an increase in area per molecule
in DOPE−CHSa in comparison to DOPE−CHOL.
PEGylation does not affect the extent of H-bond formation
between DOPE−DOPE, DOPE−CHOL, and DOPE−CHS;
however, it reduces the number of H-bonds between DOPE
and CHSa. Interestingly, the number of lipid−PEG H-bonds is
two times greater in the PEG−DOPE−CHS bilayer in
comparison to the two other bilayers.
In Section 3.1, we have already demonstrated that the area
per molecule in DOPE−CHOL and DOPE−CHSa bilayers are
similar, while in DOPE−CHS, it is smaller. This result seems
to be in disagreement with prior studies on DOPC and DPPC,
where the effects of CHOL on membrane properties were
stronger than those of CHS and CHSa.30,40 However, for the
case of DOPE, the number of steroid−DOPE H-bonds is
doubled for the case of CHSa/CHS in comparison to that for
CHOL. This probably explains the observed difference
between PC- and PE-based bilayers.
3.4. Order Parameter and Lipid Mass Density Profiles.
Figure 4A shows the profile of the deuterium order parameter
along the Sn-1 acyl chains of the lipids. The deuterium order
parameter is related to the surface area of the lipids through a
direct inverse relationship.64 A higher deuterium order
parameter generally means a more compact bilayer. The
most ordered lipid tails are observed in bilayers containing
CHS, which are also characterized by the smaller surface area
Figure 2. Average area per molecule.
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per lipid. In all cases, the lipid tail ordering was observed to be
reduced by PEGylation.
Figure 4B shows the mass density profiles of the lipids in the
simulated systems. The mass density profile shows the
membrane thickness, also related to the order parameter;
when the extent of lipid ordering is increased, the bilayer
becomes thicker and density increases, and thus the value of
the density in the profile will increase. This trend is present in
the data shown in Figure 4B. In non-PEGylated bilayers, the
density has the highest value and the bilayer is thickest for the
DOPE−CHS membrane; in the DOPE−CHOL and DOPE−
CHSa bilayers, the density is reduced and the bilayer is
thinner. The presence of PEGylated lipids decreases the
density and the bilayer thickness, though this effect is small for
the case of the DOPE−CHSa bilayer.
3.5. Ion Contacts with Bilayer and PEG. We next
calculated the contacts of the Na+ ions with both the bilayers
and PEG (Figure 5). Figure 5 shows two clear trends; first, in
bilayers containing CHSa, the ion binding of Na+ is the
strongest, and second, the presence of PEGylated lipids
decreases the extent of Na+ binding. The effect of the presence
of PEG on Na+ binding is strongest in the bilayers with neutral
steroids and weakest in the bilayers containing CHSa.
Adsorption of Na+, K+, or arginine due to deprotonation of
CHMS was observed in a prior MD simulation study.66
The results of this section must be interpreted with caution
as recent studies of PC bilayers have shown that the extent to
which cations bind to a neutral lipid bilayer is severely
overestimated.67 Thus, we can expect similar problems
concerning PE lipids; however, in comparison to DOPC, we
observed a reduced number of ions adsorbing to the water
membrane interface of DOPE bilayers. Conversely, negatively
charged lipids are expected to bind cations, including
monovalent cations,68,69 although, as far as we are aware, no
experimental studies on CHSa have so far been carried out.
3.6. PEG Penetration into Lipid Bilayers. We next
calculated the mass density profiles for the PEG polymer in all
systems, along the bilayer normal. We observed a striking
difference between the behavior of PEG in DOPE bilayers (see
Figure 6) and that of the DSPC with the cholesterol bilayer
Figure 3. Partial mass density profiles of water relative to the position of the phosphate head group peak (A). Number of bilayer−water contacts
(shown in bar graphs with values on the left-hand side Y-axis) and number of bilayer−water H-bonds (in line graphs with values on the right-hand
side Y-axis) (B). Percentage of area of the steroid head groups covered by other components of the system (C).
Table 2. Number of Bilayer−PEG, Interlipid, and Lipid−
Steroid H-Bonds
system name DOPE−DOPE DOPE−steroid bilayer−PEG
DOPE−CHOL 78.82 ± 8.91 32.95 ± 4.56
DOPE−CHS 91.02 ± 7.92 57.52 ± 4.95
DOPE−CHSa 93.08 ± 8.37 75.83 ± 5.43
PEG−DOPE−CHOL 81.11 ± 7.28 33.74 ± 4.20 13.25 ± 6.08
PEG−DOPE−CHS 92.38 ± 8.17 56.82 ± 5.03 26.71 ± 4.10
PEG−DOPE−CHSa 88.86 ± 7.72 66.51 ± 5.66 14.71 ± 3.13
Figure 4. Deuterium order parameter along the Sn-1 tail (A) and mass density profile results for the lipid component (B).
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(Doxil formulation) studied in our previous publication;44 for
the case of the PC system, PEG is predominantly located
outside the bilayer with a clear, smaller, secondary peak
completely inside the bilayer core and a reduced density of
PEG between these two locations at the position of the lipid
head groups (inset in Figure 6A). In the case of the DOPE
bilayers, in contrast, we do not see the same two-peak
distribution, but rather a single peak at roughly the position of
the phosphate head group; PEG locates to the position of the
head groups to a far greater extent (see Figure 6). The
behaviors of the three DOPE systems are qualitatively similar;
however, the extent of penetration into the membrane is
decreased for the system with CHSa in comparison to the
others. This observed penetration of PEG into the DOPE
bilayer can be seen as the cause of the significantly lower lipid
tail order parameter value for PEGylated DOPE systems in
comparison to non-PEGylated DOPE systems that we
observed (Figure 4A).
4. DISCUSSION
To understand why PEGylation reduces the sensitivity of pH-
sensitive liposomes and, additionally, how CHSa stabilizes
DOPE bilayers and how the change from CHSa to CHS
destabilizes them, we have conducted MD simulations of
DOPE systems containing CHOL, CHS, and CHSa with and
without PEG. Since the stabilization and destabilization of the
DOPE ensemble result from the phase transition, using our
results and those obtained by experimental evaluations, we
attempt to justify this observed behavior in the context of lipid
hydration and the dynamic molecular shape theory applied to
lipids, introduced by Cullis et al.70
Replacing PC with PE in the lipid head groups of a
membrane is known to increase the hydrophobicity of the
membrane surface,71 thus resulting in an increased tendency
for DOPE bilayers to undergo a lamellar-to-hexagonal phase
transition.31 The low hydration extent of DOPE is related to
the small size of the DOPE head group and formation of
intermolecular H-bonds between amine and phosphoryl
groups of adjacent DOPE molecules.31 The network of H-
bonds plays an important role in the phase behavior of DOPE
lipids;72 H-bonds between adjacent DOPE molecules replace
some of the PE−water H-bonds,73 which diminishes water
penetration in the polar head group region and reduces the
polarity of the PE head groups.71 Based on our results, CHSa
stabilizes the DOPE lipid membrane through increasing the
hydrophilicity of the bilayer surface, and as we can see in
Figure 3B, the number of bilayer−water H-bonds is
significantly greater for the systems with CHSa than those
with CHOL. When CHSa changes into CHS, the bilayer
surface is dehydrated and a large reduction in the number of
bilayer−water H-bonds is observed.
In addition to the head groups, as the polar components of
the bilayer, it has been experimentally proven that the packing
of the lipid chains would affect the extent of lipid hydration.74
In our simulations, we observed that DOPE−CHS, with the
highest extent of lipid tail ordering among non-PEGylated
systems, has the lowest extent of bilayer−water H-bonds in
comparison to the other non-PEGylated systems.
The ability of lipids to exist in various phases can be
explained by dynamic molecular shape theory; there are three
varieties of shapes available for lipids based on the ratio of the
cross-sectional area of the acyl chain to the area of the head
Figure 5. Percentage of Na+ ions in contact with the bilayers in non-PEGylated systems (A) and percentage of Na+ ions in contact with the bilayers
and PEG chains of the PEGylated systems (B).
Figure 6. Mass density profile of PEG relative to the position of the
phosphate head group peak (A) and visualization of the final
configurations of the system in the last frame of the simulation of
PEG−DOPE−CHOL (B), PEG−DOPE−CHS(C), and PEG−
DOPE−CHSa (D). Phosphate atoms are colored as green and PEG
chains as red. All other components of the systems were removed for
clarity. The inset in Figure 6A represents the PEG mass density profile
of PEG5%−DSPC−CHOL33% studied in our previous publication (ref
44).
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group. Due to its small head group and bulky acyl chains,
DOPE is considered as a cone-shaped lipid,31 which forms
non-bilayer phases, for example, the hexagonal (HII) phase.
Cylindrical-shaped lipids like PC have a similar cross-sectional
area of the head group and acyl chains and form lamellar
phases. Inverted cone-shaped lipids have a larger head group in
comparison to the acyl chains and tend to form micelles in
aqueous solutions.23
Regarding the concept of the dynamic molecular shape of
lipids, stabilization of cone-shaped lipids in the bilayer phase is
possible by either reducing the ratio of the cross-sectional area
of the acyl chain to the area of the head group24 or mixing
cylindrical lipids like PC or inverted cone-shaped lipids like
PEGylated lipids with cone-shaped lipids.23 Reducing the ratio
of the cross-sectional area of acyl chains to the area of the head
group is possible through increasing the area of the head group
either by (1) decreasing the intermolecular interaction of the
head groups, which inhibits the lateral expansion of the
bilayer,24,73 (2) binding cations with the head group,66 or (3)
increasing the extent of the hydration of the head group.75,76 It
is also possible to reduce the cross-sectional area of acyl chains
by increasing their order by, e.g., adding cholesterol.77,78 On
the other hand, an increase in temperature will increase the
ratio of the cross-sectional area of acyl chains to the area of the
head group, leading to a phase transition from the lamellar
phase to the hexagonal phase.79 Also, low hydration is a factor
promoting the formation of hexagonal phases.80 Finally,
vitamin E (α-tocopherol) promotes formation of the hexagonal
phase by an alternative, more complex mechanism.81
In our simulations, we attempt to determine how the change
of CHSa to CHS triggers the destabilization of DOPE bilayers.
We observed that when DOPE−CHSa changes to DOPE−
CHS, a reduction in the head group area occurs, which, in turn,
based on molecular dynamic shape theory, could possibly
facilitate the phase transition of DOPE bilayers from the
lamellar phase to the hexagonal phase. This reduction in the
area per lipid occurs due to the reduction in the number of
bound Na+ ions and water molecules hydrating the bilayer
(Figures 3B and 5). Our results agree with the prior studies of
Klasczyk et al., who conducted MD simulations on bilayers
composed of only CHSa; they observed all cations in the
simulation to be adsorbed by the CHSa. Following this
observation, they emphasized the importance of dynamic
molecular shape theory and attributed the stabilization of the
CHSa bilayer to the increase in the effective head group
volume of CHSa due to cation binding to its head group.66
In our simulations, we also observed the DOPE−CHSa
bilayer to adsorb all of the Na+ ions in the solution, while
DOPE−CHS adsorbs 60% of the Na+ ions. These numbers are
likely overestimated due to the overbinding of Na+ ions to the
lipid head groups; this results from the lack of explicit
polarizability in the force field.67 Thus, this remains a
qualitative observation that indicates a large difference in the
behavior of the two systems; however, the binding of cations to
bilayers containing negatively charged lipids is supported
experimentally.68,69,82 Additionally, simulations performed by
Klasczyk et al. indicated that CHSa attracts and binds counter
ions while CHS did not.66 These simulations were performed
with the GROMOS87 force field, which seems to be less
affected by the lack of explicit polarizability.
Based on our results, PEG stabilizes DOPE−CHMS
liposomes by increasing the area per lipid which, based on
molecular dynamic shape theory, prevents the phase transition
of the DOPE bilayers from lamellar to hexagonal phase. We
observed significant penetration of PEG into the DOPE
bilayer; this penetration was greater than the penetration of
PEG into the bilayers composed of PC lipids that we studied in
our previous works.2,42−45 This effect can be attributed to the
high number of bilayer−PEG H-Bonds that cannot occur in
the case of PC lipids as a result of the lack of H-bond donors in
both PEG and the PC head groups. This observation is in
agreement with the work of Holland et al., who reported that
the addition of PE−PEG to a mixture of DOPE−CHOL that
adopts a hexagonal phase when hydrated under physiological
conditions stabilizes the mixture in a bilayer conformation.23
They explained their observation in terms of the dynamic
molecular shape concept, where the inverted cone-shaped PE−
PEG stabilizes a mixture of cone-shaped lipids.
5. CONCLUSIONS
Based on the results we obtained from our simulations, we
found out that (A) CHSa stabilizes the DOPE lipid membrane
by increasing the hydrophilicity of the bilayer surface, (B)
when CHSa changes to CHS by pH reduction, DOPE bilayers
are destabilized due to a reduction in bilayer hydrophilicity and
a reduction in the area per lipid, and (C) PEG stabilizes DOPE
bilayers into the lamellar phase by increasing the area per lipid
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Javanainen, M.; Manna, M.; Rog, T.; Hof, M.; Vattulainen, I.;
Jungwirth, P. Experimental determination and computational
interpretation of biophysical properties of lipid bilayers enriched by
cholesteryl hemisuccinate. Biochim. Biophys. Acta, Biomembr. 2015,
1848, 422−432.
(31) Torchilin, V. P.; Zhou, F.; Huang, L. pH-sensitive liposomes. J.
Liposome Res. 1993, 3, 201−255.
(32) Paré, C.; Lafleur, M. Polymorphism of POPE/cholesterol
system: a 2H nuclear magnetic resonance and infrared spectroscopic
investigation. Biophys. J. 1998, 74, 899−909.
(33) Bentz, J.; Ellens, H.; Lai, M.-Z.; Szoka, F. C. On the correlation
between HII phase and the contact-induced destabilization of
phosphatidylethanolamine-containing membranes. Proc. Natl. Acad.
Sci. U.S.A. 1985, 82, 5742−5745.
(34) Ellens, H.; Bentz, J.; Szoka, F. C. Proton-and calcium-induced
fusion and destabilization of liposomes. Biochemistry 1985, 24, 3099−
3106.
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